Understanding PMS, PMDD, and the Neuroendocrine Science Behind Menstrual Mood Disorders
Over the past decade, public conversations about menstruation have expanded significantly. As we learn more about the biochemical foundations and physical aspects of the menstrual cycle, science has begun to uncover the deeper interplay between sex hormones and neurotransmitters—an interplay that creates either a smooth menstrual cycle or the disruptive symptoms associated with PMS and its more severe form, PMDD.
This blog explores the latest scientific understanding of PMS/PMDD and highlights why advanced hormone and neurotransmitter testing.
A Brief Overview of PMS & PMDD
Premenstrual syndrome (PMS) affects a large portion of women of reproductive age, with symptoms occurring cyclically around menstruation. In some cases, symptoms escalate in severity and frequency, evolving into premenstrual dysphoric disorder (PMDD).
Research shows strong associations between:
- Estrogen & progesterone and the neurotransmitter serotonin
- Cortisol and norepinephrine, which influence stress responses
- Allopregnanolone, a neurosteroid metabolite of progesterone, and the GABA system, which appears to be profoundly altered in individuals with PMDD
These interactions shape how the brain and body respond throughout the menstrual cycle.
Clinical Manifestations of PMS
Up to 80% of women experience at least mild premenstrual symptoms, while nearly 50% report moderate or severe symptoms. PMS can include more than 150 different complaints, such as:
Emotional & Cognitive Symptoms:
– depressed mood
– irritability
– anxiety
– mood swings
– tension
– loss of control
– difficulty concentrating
– hopelessness
Physical Symptoms:
– breast tenderness
– abdominal pain
– water retention
– lethargy
– sleep disturbances
Fortunately, no one experiences all of these symptoms at once.
Timing Determines Diagnosis
PMS diagnosis is based entirely on symptom timing. In a typical 25–32 day cycle:
- Symptoms may begin soon after ovulation
- Peak during the last 5 days of the cycle
- Continue into the first 1–2 days of menstruation
For many women, this leaves only a few symptom-free days per month.
PMDD and Menstrual Magnification
Premenstrual Dysphoric Disorder (PMDD)
A severe, debilitating luteal-phase disorder affecting 3–8% of menstruating women. Symptoms mirror PMS but are significantly more intense and life-disrupting.
Menstrual Magnification
Existing medical or psychological conditions may worsen premenstrually, including:
- depression, anxiety, panic disorder
- migraines
- epilepsy
- asthma
- IBS
- diabetes
- chronic fatigue
- autoimmune disorders
What Causes PMS & PMDD?
The Neuroendocrine Hypothesis
The exact cause remains unclear, but the leading theory focuses on heightened sensitivity to normal hormonal fluctuations, especially during the luteal phase.
Hormones and neurotransmitters share pathways and receptor sites in the brain. Variability in:
- progesterone
- estradiol
- allopregnanolone
- serotonin
- GABA
may cause some women to react intensely to normal hormonal shifts.
The Progesterone–Allopregnanolone–GABA Connection
After ovulation, progesterone increases and is converted into allopregnanolone, a neurosteroid that:
- modulates GABA-A receptors
- reduces anxiety
- promotes calmness
- improves cognitive functioning
- protects against neuroinflammation
In most women, these effects are stabilising.
In others, particularly those with PMDD, allopregnanolone triggers severe mood shifts.
Why?
Not because the hormone levels differ—studies show no difference in serum allopregnanolone between PMDD and non-PMDD women.
The issue lies in the brain’s response to allopregnanolone.
The Allopregnanolone Paradox
Allopregnanolone normally has calming effects. Yet in PMDD:
- Moderate luteal-phase levels worsen symptoms
- Very high levels (e.g., from progesterone therapy) improve symptoms
- Suppression of ovarian hormones can eliminate symptoms altogether
- 5α-reductase inhibitors reducing allopregnanolone formation also reduce PMDD symptoms
This paradox strongly supports the theory of GABA-A receptor dysfunction.
GABAergic System Alterations in PMDD
Recent studies reveal:
- Women with PMDD show structural differences in GABA-A receptor subunits
- They demonstrate hypersensitivity to allopregnanolone
- Brain GABA levels rise during the luteal phase in PMDD (but fall in non-PMDD women)
This abnormal receptor behaviour likely prevents normal adaptation to hormonal change—producing the extreme emotional sensitivity typical of PMDD.
The Estradiol–Serotonin Connection
Estradiol profoundly influences serotonin by regulating:
- synthesis
- degradation
- receptor expression
Women with PMS or PMDD appear more sensitive to serotonin fluctuations, especially when:
- estradiol levels fall in the luteal phase
- serotonin production decreases
- blood serotonin levels decline
- Genetic factors may contribute, including:
- estrogen receptor α polymorphisms
- serotonin receptor 5HT-1A variants
Both influence vulnerability to PMS/PMDD.
Why SSRIs Are the Gold-Standard Treatment
SSRIs are effective for moderate–severe PMS and PMDD and are taken only during the symptomatic luteal phase.
Their rapid action may result from their ability to:
- increase brain levels of the calming neurosteroid allopregnanolone
- modulate serotonin levels
- stabilise mood quickly
This mechanism supports the neurosteroid hypothesis of PMDD.
Stress Response and the HPA Axis in PMS/PMDD
Patients with menstrual mood disorders often show:
- blunted cortisol responses
- altered norepinephrine reactivity
- impaired HPA-axis signalling
- abnormal cortisol awakening patterns
These stress-related irregularities may intensify affective symptoms during the luteal phase.
Final Thoughts
Understanding PMS and PMDD is not simply about mood—it is about the complex neuroendocrine dance between hormones, neurotransmitters, and brain receptors. Increased awareness of menstrual mood disorders is crucial, especially as these conditions remain under-recognised despite their significant impact on women’s health.
With ongoing research, better diagnostic tools, and personalised testing options from Hormone Lab UK, women can gain the clarity they need to understand their symptoms and explore effective treatment strategies.
Explore Female Hormone and Neurotransmitters Test Profiles
Hormone Lab UK is the official UK test provider for ZRT Laboratory, offering the most advanced hormone, neurotransmitter, and endocrine testing available. Click below links to see our hormone and neurotransmitters test profiles.